Novartis AGNOVN:VTX

87.60
0.550 / 0.62%
4.91m
23.21%
0.8155
Close in CHFToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Sep 12 2014 16:31 BST.

Summary

On Friday, Novartis AG (NOVN:VTX) closed at 87.60, 0.74% below its 52-week high of 88.25, set on Sep 11, 2014.

52-week range
Today
66.30
Oct 10 2013
88.25
Sep 11 2014
Markit short selling activity
Low
Medium
High
Open88.10
Day high--
Day low--
Bid--
Offer--
Previous close87.60
Average volume5.66m
Shares outstanding2.71bn
Free float2.54bn
P/E (TTM)24.69
Market cap236.48bn CHF
EPS (TTM)3.54 CHF
Annual div (TTM)1.59 CHF
Annual div yield (TTM)1.82%
Div ex-dateFeb 27 2014
Div pay-dateMar 04 2014
Last IC View
The last IC recommendation on Novartis AG shares was Hold at 72.25 on 26 Nov 2013
Read the full article
Data delayed at least 15 minutes, as of Sep 12 2014 16:31 BST.

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
Novartis AG+1.39%+12.45%+23.03%+23.21%+74.29%
ALL SHARE CH X INDEX+0.03%+5.27%+8.21%+10.63%+38.75%
CH/HEALTH CARE+0.94%+8.17%+13.69%+17.52%--
CH/PHARMACEUTICALS+1.00%+8.23%+13.27%+16.46%--
Data delayed at least 15 minutes, as of Sep 12 2014 16:31 BST.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.